JPRN-jRCTs011180020
Completed
未知
Hypoxia imaging with 18F-Misonidazole PET in brain metastasis - FMISO-BM
Takashi Mori0 sites25 target enrollmentMarch 19, 2019
Conditionsmetastatic brain tumor
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- metastatic brain tumor
- Sponsor
- Takashi Mori
- Enrollment
- 25
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
The FMISO accumulation positivity rate of metastatic brain tumors was 39.8%, and the risk ratio of tumor regrowth in the accumulation positive group to the FMISO accumulation negative group was 4.60 (95% CI 1.23-17.2), p = 0.0235, indicating a significantly higher risk of regrowth.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\)metastatic brain tumor whose maximum diameter is equal to or above 5mm in MRI.
- •2\)no treatment history with radiotherapy or surgery to metastatic brain tumor.
- •3\)no meningitis carcinomatosa and dissemination in MRI.
- •4\)KPS equal to or above 70%.
- •5\)Pathologically (histologically or cytologically) proven diagnosis from extra cranial lesion.
- •6\)Patients must sign a study\-specific informed consent prior to study entry.
Exclusion Criteria
- •1\)patient who can rest in dorsal position for about one hour
- •2\)patient with severe claustrophobia
- •4\)expectant and nursing mothers
- •5\)patient judged unsuitable as a trial subject by the principal investigator
Outcomes
Primary Outcomes
Not specified
Similar Trials
Terminated
Phase 2
FMISO-PET in Brain Tumors and SCS EffectMalignant GliomaNCT01868906Bernardino Clavo, MD, PhD6
Completed
Not Applicable
Hypoxia imaging with 18F-Misonidazole PET in brain metastasismetastatic brain tumorJPRN-UMIN000014572Departments of Radiation Oncology, Hokkaido University Hospital25
Not yet recruiting
Not Applicable
hypoxic imaging for brain tumor with 18F-fluoromisonidazole PETbrain tumorJPRN-UMIN000042213Kyoto University Graduate School of Medicine170
Completed
Phase 1
Clinical Evaluation of the New Hypoxia Imaging Agent HX4Head and Neck CancerLung CancerLiver CancerNCT01213030Siemens Molecular Imaging12
Completed
Phase 2
HYPONCO - Hypoxia in Brain TumorsAnaplastic GliomaNCT01200134University Hospital, Caen39